Roivant Sciences Ltd. (ROIV)
| Market Cap | 19.62B +178.0% |
| Revenue (ttm) | 13.31M -56.4% |
| Net Income | -809.24M |
| EPS | -1.17 |
| Shares Out | 715.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,616,021 |
| Open | 28.24 |
| Previous Close | 28.14 |
| Day's Range | 27.06 - 28.32 |
| 52-Week Range | 10.58 - 30.33 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 28.94 (+5.58%) |
| Earnings Date | May 28, 2026 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monocl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $28.94, which is an increase of 5.58% from the latest price.
News
Roivant Sciences Transcript: Study result
A new combined phase II-B/III trial for brepocitinib in lichen planopilaris has begun, targeting a severe, high-unmet-need scalp disorder with no approved therapies. The phase III TED study for batoclimab did not meet its primary endpoint, but data support ongoing Graves’ disease programs with next-generation FcRn inhibitors.
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA...
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA...
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
DURHAM, N.C., March 28, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics, a clinical-stage biotechnology company focused on developing targeted therapeutics in autoimmune disease, announced today the pu...
Roivant Sciences Transcript: Leerink Global Healthcare Conference 2026
A transformative period is underway with the launch of brepocitinib for dermatomyositis expected by end of Q3, supported by a robust pipeline including NIU, cutaneous sarcoidosis, and mosliciguat for PH-ILD. Additional FcRn inhibitor data and a major Graves' disease readout are anticipated.
Roivant Sciences Transcript: Status update
A $2.25 billion global settlement with Moderna resolves all COVID-19 vaccine patent litigation, including a $950 million upfront payment and a $1.3 billion contingent on appeal. Proceeds will fund pipeline investments and a $1 billion share buyback, while Pfizer-BioNTech litigation continues.
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its ...
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Roivant Sciences Transcript: TD Cowen 46th Annual Health Care Conference
Priority review accelerates a key therapy’s launch to September, with broad label ambitions and strong physician enthusiasm for steroid-sparing benefits. Multiple late-stage trials in NIU, cutaneous sarcoidosis, PH-ILD, and Graves’ disease are progressing, with pivotal data expected this year and next.
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026 Priority Review supported by positive Phase 3 VALOR results, the first...
Roivant Sciences Earnings Call Transcript: Q3 2026
Positive phase II results for brepocitinib in cutaneous sarcoidosis showed strong efficacy and safety, supporting advancement to phase III. The company maintains a robust cash position and anticipates multiple pivotal readouts and potential launches in the next few years.
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV...
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced positive results from the Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). CS is a high...
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
BASEL, Switzerland and LONDON and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reporte...
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, Feb...
Roivant Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
A streamlined, capital-strong biotech is set for transformative growth, with three commercial launches and multiple pivotal data readouts expected in the next 36 months. Key assets target high unmet needs in dermatomyositis, RA, and PH-ILD, supported by robust financials and strategic flexibility.
Roivant Sciences Transcript: Investor Day 2025
The company is entering a new phase with a focused, capital-efficient strategy targeting high-value specialty indications. Multiple late-stage programs are advancing, with major data readouts and commercial launches expected from 2026 onward, supported by strong financials and a robust pipeline.
Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day
BASEL, Switzerland and LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline u...
Roivant Sciences Transcript: Jefferies London Healthcare Conference 2025
Transformative clinical progress was highlighted, with brepocitinib and FCRN franchises advancing in multiple indications. 2026 will bring key data readouts and potential market expansion, while business development remains focused on high-impact opportunities.
Roivant Sciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Strong clinical momentum with brepocitinib and Immunovant assets, multiple pivotal and POC readouts expected through 2027, and a robust cash position supports ongoing R&D, business development, and share buybacks. Major LNP litigation milestones are upcoming, with potential for significant financial impact.
Roivant Sciences Earnings Call Transcript: Q2 2026
Major clinical milestones achieved with positive phase III data in DM and durable remission in Graves'. Strong cash position of $4.4B supports a robust late-stage pipeline and upcoming NDA filings, with significant commercial and clinical catalysts expected over the next 36 months.
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided ...
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business ...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, Nov...